BASEL, Switzerland and SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced that Fredrik Wiklund, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14th, 2025, at 2:30 p.m. Pacific Time. The Company will also participate in 1-on-1 investor meetings during the conference.
About Bright Peak Therapeutics
Bright Peak Therapeutics is a clinical-stage biotechnology company pioneering multifunctional immunotherapies to treat cancer. Leveraging innovative protein engineering and a proprietary chemical protein synthesis and conjugation platform, Bright Peak is building a robust pipeline of first-in-class multifunctional molecules. The company's lead program, BPT567, is a bifunctional PD1-IL18 immunoconjugate currently in Phase 1/2a clinical trials. With headquarters in Basel, Switzerland, and San Diego, CA, Bright Peak is backed by top-tier healthcare investors. For more information, visit www.brightpeaktx.com.
Contact:
info@brightpeaktx.com


Globe newswire
About author
Related posts
G1 Therapeutics to Participate in the Cowen 43rd Annual
RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a
Beam Therapeutics to Participate in the 43rd Annual Cowen
CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology
Vir Biotechnology to Participate in the Cowen 43rd
SAN FRANCISCO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that
NGM Bio to Participate in the Cowen 43rd Annual Health Care
SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio)
DICE Therapeutics to Participate at Upcoming Investor
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a
Prelude Therapeutics To Participate in Two Upcoming
WILMINGTON, Del., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq:
Monopar to Present at the 35th Annual Roth Conference
WILMETTE, Ill., March 07, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a